Research programme: monoclonal antibodies - Jinghua Pharmaceutical/Kadmon Corporation

Drug Profile

Research programme: monoclonal antibodies - Jinghua Pharmaceutical/Kadmon Corporation

Alternative Names: Anti-VEGFR2 and anti-PD-L1 monoclonal antibodies - Jinghua/Kadmon; KD-035; KD-036

Latest Information Update: 02 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kadmon Corporation
  • Developer Jinghua Pharmaceutical; Kadmon Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 20 Nov 2015 Fully human anti-VEGFR 2 and anti-PD L1 monoclonal antibodies licensed to Jinghua Pharmaceutical in China
  • 20 Nov 2015 Jinghua Pharmaceutical in-licenses technology to discover technology fully human monoclonal antibodies from Kadmon Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top